<DOC>
	<DOCNO>NCT02752113</DOCNO>
	<brief_summary>Diabetes mellitus wide-spread disease accompany strongly increase morbidity mortality due micro- macrovascular complication . However , study patient suffer diabetes mellitus type 2 ( DM 2 ) , early change impairment large small blood vessel well organ damage ( e. g. kidney ) insufficiently investigate ( 1 ) . The new substance class oral antidiabetic , i. e. SGLT-2-inhibitors ( empagliflozin ) cause increase renal excretion glucose . In addition , concurrent increase sodium excretion bring improvement vascular function thus decrease blood pressure . In EMP-REG-OUTCOME study ( 2 ) , cardiovascular mortality rate significantly low empagliflozin group ( 3.7 % versus 5.9 % ; 38 % relative RR ) compare placebo.For another new substance class , dipeptidylpeptidase-4-inhibitors , number pleiotropic effect describe ( 3 ) . In one recently conduct trial , could demonstrate positive effect linagliptin renal inflammatory parameter compare placebo ( 4 ) . Thus , combination substance class regard positive effect micro- macrocirculation , even though sufficiently prove yet , suggest . The therapy metformin long-acting insulin ( BOT ) , well twofold oral medication possible accord recommendation `` Deutsche Diabetes Gesellschaft ( DDG ) '' positional paper `` American Diabetes Association ( ADA ) '' . Accordingly , aim present paper analysis effect combine therapy empagliflozin plus linagliptin compare metformin plus insulin glargine renal vascular change type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effects Empagliflozin + Linagliptin v Metformin + Insulin Glargine Renal Vascular Changes Type 2 Diabetes</brief_title>
	<detailed_description>Diabetes mellitus , consider begin metabolic disorder , mutate predominantly vascular disease , duration extend several year or/and additional cardiovascular ( CV ) risk factor coexist , particular arterial hypertension . As consequence , treatment type 2 diabetes focus metabolic control also improve vascular structure function micro- macrocirculation ( 1 ) . Glomerular hyperfiltration hyperperfusion point alter intraglomerular hemodynamics , e.g . reduce preglomerular ( i.e . resistance afferent arteriole [ Ra ] ) resistance increase postglomerular ( i.e . resistance efferent arteriole [ Re ] ) resistance ( result increase intraglomerular pressure [ Pglom ] ) consider pivotal hemodynamic hallmark renal impairment early diabetes ( 2 ) . Endothelium dysfunction key pathogenetic process lead increase leakage albumin glomerular barrier represent pivotal determinant glomerular filtration rate ( GFR ) ( 3 ; 4 ) . Poor glycemic control related hyperperfusion increase basal nitric oxide ( NO ) activity secondary increase oxidative stress lead impaired endothelial function early diabetes ( 5 ) . Indeed , endothelial function increase reduce oxidative stress evidence result infusion vitamin C ( 6 ) . The assessment pulse wave velocity ( PWV ) , pulse wave analysis ( PWA ) , central ( aortic ) systolic pressure pulse pressure , forward backward wave amplitude tool detect early vascular change relate faster wave reflection arterial tree consider valid intermediate ( surrogate ) endpoints vascular damage ( 7 ; 8 ) . These parameter infrequently measure study type 2 diabetes ( 9 ) , mainly due lack expertise require assess vascular renal marker , lack awareness vascular change key prognostic factor type 2 diabetes . Empagliflozin novel selective inhibitor sodium-glucose cotransporter 2 ( SGLT-2 ) show improve glycemic control 12 , 24 week well 1 year ( 10 ) . Empagliflozin produce dose dependent increase glucosuria clinically meaningful change glycemic parameter type 2 diabetes ( e.g . Glycosylated Hemoglobin [ HbA1c ] ) , addition weight loss blood pressure reduction . In parallel glucosuria , sodium excrete urine loss sodium lead less reactive contraction small artery response sympathetic activity , angiotensin II catecholamine . The reduction blood pressure might relate weight loss loss intravascular volume sodium content well improve vascular function . In EMPA-REG-OUTCOME trial ( 11 ) empagliflozin group significantly low rate death CV cause ( 3.7 % , vs. 5.9 % placebo group ; 38 % relative risk reduction ) , hospitalization heart failure ( 2.7 % 4.1 % , respectively ; 35 % relative risk reduction ) , death cause ( 5.7 % 8.3 % , respectively ; 32 % relative risk reduction ) . These beneficial effect hard outcome parameter might relate effect empagliflozin describe . Furthermore , among patient receive empagliflozin , admittedly increase rate genital infection increase incidence adverse event safety parameter observe . Dipeptidyl peptidase-4 ( DPP-4 ) inhibitor , new drug class antidiabetic agent , also attractive agent treat type 2 diabetes . So far , predominant focus antidiabetic efficacy , several pleiotropic effect DPP-4 inhibitor describe ( 12 ) . Indeed , observe beneficial renal effect linagliptin , e.g . preserve preglomerular resistance NO activity renal vascular bed , compare placebo , well reduced inflammatory marker ( 13 ) . Thus , combine empagliflozin linagliptin obvious antiglycemic potency safety still examine large phase 3 program ( 14 ) . Moreover , due pleiotropic effect 2 compound ( describe ) , synergistic beneficial effect micro- macrocirculation ( vascular renal effect ) expect ( though yet prove ) may explain great extent observe beneficial effect empagliflozin CV death total mortality ( 11 ) . According guideline combination insulin metformin still , however , consider valid well establish combination control hyperglycemia . However , accord update Position Statement American Diabetes Association ( ADA ) European Association Study Diabetes ( EASD ) advance dual oral combination , even triple oral antiglycemic therapy recommend alternative ( 15 ) . Hence , least metformin contraindicate tolerated , combination DPP-4 inhibitor SGLT-2 inhibitor may preferably choice . The goal current proposal prove hypothesis similar level glycemic control combination empagliflozin linagliptin exert beneficial effect renal vascular endothelium vascular surrogate endpoint patient type 2 diabetes oppose combination metformin insulin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus , use metformin ( 850 1000 mg twice daily ) least 2 month prior screen visit HbA1c ≥7 % Age 18 75 year Male female patient ( female child bear potential must use adequate contraceptive precaution ) Females childbearing potential within two year menopause must negative urine pregnancy test screen visit Informed consent ( § 40 Abs . 1 Satz 3 Punkt 3 AMG ) give write form . Any form diabetes mellitus type 2 diabetes mellitus Use insulin , glitazone , gliptin SGLT2 inhibitor within past 2 month HbA1c &gt; 10 % Fasting plasma glucose &gt; 240 mg/dl Any history stroke , transient ischemic attack , instable angina pectoris , myocardial infarction within last 6 month prior study inclusion UACR ≥ 300 mg/g ( early morning spot urine ) Estimated GFR ( eGFR ) &lt; 60 ml/min/1.73m² Uncontrolled arterial hypertension ( blood pressure ≥ 180/110 mmHg ) Congestive heart failure NYHA stage III IV Severe disorder gastrointestinal tract disease interfere pharmacodynamics pharmacokinetics study drug Significant laboratory abnormality serum GlutamateOxaloacetateTransaminase ( SGOT ) serum GlutamatePyruvateTransaminase ( SGPT ) level 3 x upper limit normal range Drug alcohol abuse Pregnant breastfeeding patient Use loop diuretic History repetitive urogenital infection per year Body mass index &gt; 40 kg/m² Triglyceride level &gt; 1000 mg/dl High density lipoprotein ( HDL ) cholesterol level &lt; 25 mg/dl Any patient currently receive chronic ( &gt; 30 consecutive day ) treatment oral corticosteroid Patients treat severe auto immune disease e.g . lupus Participation another clinical study within 30 day prior visit 1 Individuals risk poor protocol medication compliance Subject give write consent , pseudonymous data transfer line duty documentation duty notification accord § 12 § 13 GCPV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>diabetes mellitus type 2</keyword>
	<keyword>Metformin</keyword>
	<keyword>Micro- macrocirculation</keyword>
	<keyword>HbA1c &gt; = 7 %</keyword>
</DOC>